THE EFFICACY OF SWITCHING FROM OTHER BASAL INSULIN TO INSULIN DEGLUDEC AMONG PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES ON INTENSIVE INSULIN THERAPY

被引：0
|
作者：
Kakizaki, Y. [1 ]
Sasaki, J. [1 ]
Sakakura, K. [2 ]
Tamaru, S. [1 ]
Shikuma, J. [1 ]
Ito, R. [1 ]
Miwa, T. [1 ]
Odawara, M. [1 ]
机构：
[1] Tokyo Med Univ, Dept Diabet Endcrinol & Metab, Tokyo 1608402, Japan
[2] Tokyo Med Univ, Dept Pharm, Tokyo 1608402, Japan
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2014年 / 106卷
关键词：
D O I：
10.1016/S0168-8227(14)70552-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO258
引用
收藏
页码：S181 / S181
页数：1
相关论文
共 50 条
  • [31] Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Katamine, Aki
    Kondo, Yuichiro
    Babazono, Tetsuya
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (11) : 1983 - 1991
  • [32] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Kondo, Yuichiro
    Katamine, Aki
    Shimizu, Mika
    Kubota, Ryo
    Suda, Rika
    Babazono, Tetsuya
    DIABETOLOGY INTERNATIONAL, 2024, 15 (02) : 237 - 243
  • [33] EFFICACY AND SAFETY OF SWITCHING FROM INSULIN DETEMIR TO INSULIN DEGLUDEC WITH MEALTIME INSULIN ASPART IN PEDIATRIC PATIENTS WITH TYPE 1 DIABETES. AN OBSERVATIONAL PROSPECTIVE STUDY
    Elbarbary, Nancy S.
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 45 - 45
  • [34] Intensive insulin therapy in patients with type 2 diabetes
    Bering, Balpreet
    Devendra, Devasenan
    LANCET, 2008, 372 (9640): : 716 - 717
  • [35] Efficacy and Safety of Switching from Basal Insulin to Sitagliptin in Japanese Type 2 Diabetes Patients
    Harashima, S. -I.
    Tanaka, D.
    Yamane, S.
    Ogura, M.
    Fujita, Y.
    Murata, Y.
    Seike, M.
    Koizumi, T.
    Aono, M.
    Wang, Y.
    Inagaki, N.
    HORMONE AND METABOLIC RESEARCH, 2013, 45 (03) : 231 - 238
  • [36] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Junko Oya
    Tomoko Nakagami
    Yukiko Hasegawa
    Yuichiro Kondo
    Aki Katamine
    Mika Shimizu
    Ryo Kubota
    Rika Suda
    Tetsuya Babazono
    Diabetology International, 2024, 15 : 237 - 243
  • [37] Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes
    Kerlan, Veronique
    Gouet, Didier
    Marre, Michel
    Renard, Eric
    ANNALES D ENDOCRINOLOGIE, 2013, 74 (5-6) : 487 - 490
  • [38] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    DIABETES, 2017, 66 : A252 - A252
  • [39] An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
    Evans, Marc
    Billings, Liana K.
    Hakan-Bloch, Jonas
    Slothuus, Ulla
    Abrahamsen, Trine J.
    Andersen, Andreas
    Jansen, Jeroen P.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 340 - 347
  • [40] The Efficacy of Insulin Degludec in Children and Adolescents with Type 1 Diabetes
    Bruzzi, Patrizia
    Maltoni, Giulio
    Predieri, Barbara
    Zucchini, Stefano
    Iughetti, Lorenzo
    HORMONE RESEARCH IN PAEDIATRICS, 2016, 86 : 85 - 85
12345